We compared our results obtained with both RNase I and RNase T1 (4181 targets) with IGF2BP3 targets identified by the PAR-CLIP method in HEK293 (Hafner et al. 2010), by other CLIP approaches in human pluripotent stem cells (Conway et al. 2016), B-acute lymphoblastic leukemia (B-ALL) (Palanichamy et al. 2016), hepatocellular carcinoma (HepG2) (ENCODE [Dunham et al. 2012]), and pancreatic ductal adenocarcinoma (PL45 and Panc1) (Ennajdaoui et al. 2016) (6456 targets) (Supplemental Table 2). This evidence concerns the gene IGF2BP3 and hepatocellular carcinoma.